Nykredit A S Purchases New Position in Boston Scientific Corporation $BSX

Nykredit A S purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, Holdings Channel.com reports. The firm purchased 582,416 shares of the medical equipment provider’s stock, valued at approximately $24,858,000.

A number of other large investors have also added to or reduced their stakes in the company. Kelleher Financial Advisors purchased a new position in shares of Boston Scientific in the second quarter valued at $25,000. FWL Investment Management LLC bought a new position in Boston Scientific during the second quarter valued at $26,000. Swiss RE Ltd. purchased a new position in shares of Boston Scientific in the 4th quarter worth $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific in the 4th quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Boston Scientific in the 1st quarter worth about $28,000. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Royal Bank Of Canada lowered their price target on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. Piper Sandler reissued an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a research note on Friday, June 12th. Citigroup decreased their price objective on Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Finally, Wells Fargo & Company dropped their target price on Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a report on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction dated Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David C. Habiger purchased 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 194,522 shares of company stock valued at $9,385,210 in the last quarter. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Down 3.0%

Shares of NYSE BSX opened at $46.93 on Friday. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The firm has a 50-day simple moving average of $46.83 and a two-hundred day simple moving average of $55.79. The company has a market cap of $68.01 billion, a P/E ratio of 19.00, a PEG ratio of 1.12 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The company’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a share buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.